glycopyrronium bromide (glycopyrrolate) - Keputusan Carian

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

novistig glycopyrronium bromide (glycopyrrolate)/neostigmine methylsulfate 0.5 mg/2.5 mg per 1 ml injection solution ampoule

boucher & muir pty ltd - neostigmine methylsulfate, quantity: 2.5 mg; glycopyrronium bromide, quantity: 0.5 mg - injection, solution - excipient ingredients: water for injections; citric acid; dibasic sodium phosphate dodecahydrate; sodium hydroxide - reversal of residual non-depolarising (competitive) neuromuscular block.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

glycopyrrolate accord glycopyrrolate 0.2 mg/1 ml injection ampoules

accord healthcare pty ltd - glycopyrronium bromide, quantity: 0.2 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium chloride - 1. as a preoperative antimuscarinic to reduce salivary, tracheobronchial and pharyngeal secretions, and to reduce the acidity and volume of the gastric contents.,2. as a preoperative or intra-operative antimuscarinic to attenuate or prevent intra- operative bradycardia associated with the use of suxamethonium or due to cardiac vagal reflexes.,3. to protect against the peripheral muscarinic actions (e.g. bradycardia and excessive secretions) of anticholinesterases such as neostigmine or pyridostigmine given to reverse neuromuscular blockade produced by non-depolarising muscle relaxants.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

glycopyrrolate accord glycopyrrolate 0.6 mg/3 ml injection ampoules

accord healthcare pty ltd - glycopyrronium bromide, quantity: 0.2 mg/ml - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid - 1. as a preoperative antimuscarinic to reduce salivary, tracheobronchial and pharyngeal secretions, and to reduce the acidity and volume of the gastric contents.,2. as a preoperative or intra-operative antimuscarinic to attenuate or prevent intra- operative bradycardia associated with the use of suxamethonium or due to cardiac vagal reflexes.,3. to protect against the peripheral muscarinic actions (e.g. bradycardia and excessive secretions) of anticholinesterases such as neostigmine or pyridostigmine given to reverse neuromuscular blockade produced by non-depolarising muscle relaxants.